Jeffrey R. Jackson

5.0k total citations · 2 hit papers
45 papers, 3.4k citations indexed

About

Jeffrey R. Jackson is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Jeffrey R. Jackson has authored 45 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 14 papers in Oncology and 14 papers in Cell Biology. Recurrent topics in Jeffrey R. Jackson's work include Microtubule and mitosis dynamics (14 papers), Cancer-related Molecular Pathways (8 papers) and Ubiquitin and proteasome pathways (5 papers). Jeffrey R. Jackson is often cited by papers focused on Microtubule and mitosis dynamics (14 papers), Cancer-related Molecular Pathways (8 papers) and Ubiquitin and proteasome pathways (5 papers). Jeffrey R. Jackson collaborates with scholars based in United States, United Kingdom and Denmark. Jeffrey R. Jackson's co-authors include James D. Winkler, Michael Seed, D. A. Willoughby, Pearl S. Huang, Mohammed M. Dar, Denis R. Patrick, Lisa A. Marshall, Amy Roshak, Omid Hamid and Scott D. Chasalow and has published in prestigious journals such as Journal of the American Chemical Society, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Jeffrey R. Jackson

45 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An immune-active tumor microenvironment favors clinical response to ipilimumab

2011 593 citations Rui‐Ru Ji, Scott D. Chasalow et al. Cancer Immunology Immunotherapy profile →
The codependence of angiogenesis and chronic inflammation

1997 590 citations Jeffrey R. Jackson, James D. Winkler et al. profile →

Peers

Countries citing papers authored by Jeffrey R. Jackson

Since Specialization

Citations

This map shows the geographic impact of Jeffrey R. Jackson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey R. Jackson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey R. Jackson more than expected).

Fields of papers citing papers by Jeffrey R. Jackson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey R. Jackson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey R. Jackson. The network helps show where Jeffrey R. Jackson may publish in the future.

Co-authorship network of co-authors of Jeffrey R. Jackson

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey R. Jackson. A scholar is included among the top collaborators of Jeffrey R. Jackson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey R. Jackson. Jeffrey R. Jackson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy 2016 ·Annals of Oncology ·Quincy S. Chu, Ben Markman, Natasha B. Leighl, Lee M. Krug, Charles M. Rudin, Deanne Lathers, Paul Basciano, Paula M. Fracasso, Georgia Kollia, Penny Phillips, Gerry Kolaitis, Daphne Williams, Jeffrey R. Jackson, Neal Ready	3
2	IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines 2014 ·Molecular Cancer Therapeutics ·Fei Huang, Chang Han, Ann Greer, Stephen Hillerman, Karen A. Reeves, Warren Hurlburt, John Cogswell, (unknown), Zhenhao Qi, Craig Fairchild, Rolf-Peter Ryseck, Tai W. Wong, Friedrich Graf Finckenstein, Jeffrey R. Jackson, Joan M. Carboni	25
3	Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab 2012 ·Cancer Immunology Immunotherapy ·Vafa Shahabi, Gena S. Whitney, Omid Hamid, Henrik Schmidt, Scott D. Chasalow, Suresh Alaparthy, Jeffrey R. Jackson	63
4	An immune-active tumor microenvironment favors clinical response to ipilimumab breakdown → 2011 ·Cancer Immunology Immunotherapy ·Rui‐Ru Ji, Scott D. Chasalow, Lisu Wang, Omid Hamid, Henrik Schmidt, John Cogswell, Suresh Alaparthy, David M. Berman, Maria Jure–Kunkel, Nathan O. Siemers, Jeffrey R. Jackson, Vafa Shahabi	593
5	Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability 2010 ·Molecular Cancer Therapeutics ·Yan Degenhardt, Joel Greshock, Sylvie Laquerre, Aidan G. Gilmartin, Junping Jing, Mark C. Richter, Xiping Zhang, Maureen R. Bleam, Wendy S. Halsey, Ashley M. Hughes, Christopher Moy, (unknown), Scott Powers, Kurtis E. Bachman, Jeffrey R. Jackson, Barbara Weber, Richard Wooster	73
6	Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: Potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties 2010 ·Bioorganic & Medicinal Chemistry Letters ·Tara Rheault, (unknown), (unknown), Ronda G. Davis‐Ward, C. Webb Andrews, Ramesh Bambal, Jeffrey R. Jackson, Mui Cheung	12
7	Distinct Concentration-Dependent Effects of the Polo-like Kinase 1–Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis 2009 ·Cancer Research ·Aidan G. Gilmartin, Maureen R. Bleam, Mark C. Richter, Symon G. Erskine, Ryan G. Kruger, (unknown), Daniel F. Hassler, Gary K. Smith, Richard R. Gontarek, (unknown), David Sutton, Melody Diamond, Jeffrey R. Jackson, Sylvie Laquerre	100
8	Integrated analysis of breast cancer cell lines reveals unique signaling pathways 2009 ·Genome biology ·Laura M. Heiser, Nicholas J. Wang, Carolyn Talcott, Keith R. Laderoute, Merrill Knapp, Yinghui Guan, Zhi Hu, Safiyyah Ziyad, Barbara L. Weber, Sylvie Laquerre, Jeffrey R. Jackson, Richard Wooster, (unknown), Joe W. Gray, Paul T. Spellman	46
9	Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding 2009 ·Bioorganic & Medicinal Chemistry Letters ·Kyle A. Emmitte, (unknown), C. Webb Andrews, (unknown), Ramesh Bambal, Stanley D. Chamberlain, Ronda G. Davis‐Ward, Hamilton D. Dickson, Daniel F. Hassler, Keith R. Hornberger, Jeffrey R. Jackson, Kevin W. Kuntz, Timothy J. Lansing, Robert A. Mook, (unknown), (unknown), (unknown), (unknown), Mui Cheung	54
10	Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden 2008 ·Journal of Human Hypertension ·Mattias Ekman, (unknown), Jeffrey R. Jackson	13
11	Targeted anti-mitotic therapies: can we improve on tubulin agents? 2007 ·Nature reviews. Cancer ·Jeffrey R. Jackson, Denis R. Patrick, Mohammed M. Dar, Pearl S. Huang	388
12	Efficacy of GSK461364, a selective Plk1 inhibitor, in human tumor xenograft models 2007 ·David Sutton, Melody Diamond, Leo F. Faucette, (unknown), Shuyun Zhang, Aidan G. Gilmartin, James M. Salovich, Mui Cheung, Kevin W. Kuntz, Sylvie Laquerre, Pearl S. Huang, Jeffrey R. Jackson	4
13	ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism 2007 ·Nature Chemical Biology ·Lusong Luo, Cynthia A. Parrish, Neysa Nevins, Dean E. McNulty, (unknown), (unknown), Valery Sudakin, Antony N. Shaw, Ruth Lehr, Huizhen Zhao, Sharon Sweitzer, Latesh Lad, Kenneth W. Wood, Roman Sakowicz, Roland S. Annan, Pearl S. Huang, Jeffrey R. Jackson, Dashyant Dhanak, Robert A. Copeland, Kurt R. Auger	92
14	Identification of Drosophila Myt1 kinase and its role in Golgi during mitosis 2002 ·Cellular Signalling ·William D. Cornwell, (unknown), Jeffrey R. Jackson	18
15	The Identification and Characterization of the Marine Natural Product Scytonemin as a Novel Antiproliferative Pharmacophore 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Christopher S. Stevenson, (unknown), Amy Roshak, Brian L. Márquez, (unknown), Jeffrey R. Jackson, Michael R. Mattern, William H. Gerwick, Robert S. Jacobs, Lisa A. Marshall	148
16	The role of platelet activating factor and other lipid mediators in inflammatory angiogenesis 1998 ·Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism ·Jeffrey R. Jackson, Brian Bolognese, (unknown), Walter C. Hubbard, Lisa A. Marshall, James D. Winkler	29
17	Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. 1997 ·PubMed ·Jeffrey R. Jackson, Jayne A.L. Minton, M Ho, Na Wei, Julia Winkler	191
18	Modulation of angiogenesis in a model of chronic inflammation 1997 ·Inflammation Research ·Jeffrey R. Jackson, Brian Bolognese, (unknown), Julia Winkler	16
19	DNA - histone interactions are sufficient to position single nucleosome juxtaposingDrosophila Adhadult enhancer and distal promoter 1993 ·Nucleic Acids Research ·Jeffrey R. Jackson, Cheeptip Benyajati	38
20	In vivostage- and tissue-specific DNA-protein interactions at theD.melanogasteralcohol dehydrogenase distal promoter and adult enhancer 1992 ·Nucleic Acids Research ·Jeffrey R. Jackson, Cheeptip Benyajati	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact